

## Special Issue

# Oral Vaccines: Challenges, Immunity and Therapeutic Advances

### Message from the Guest Editor

Oral vaccines represent a transformative approach in immunotherapy, offering non-invasive delivery and the unique ability to stimulate both mucosal and systemic immune responses. Oral vaccination is gaining increasing attention as a powerful tool for preventing and treating diseases across various fields, including infectious diseases, cancer immunotherapy, and mucosal immunity. Unlike traditional injectable vaccines, oral vaccines can stimulate both local and systemic immune responses, though their development faces complex scientific challenges. This Special Issue aims to gather cutting-edge research and comprehensive reviews that explore the development, immunological mechanisms, and clinical potential of oral vaccines. Research areas may include the following:

- Mucosal immune mechanisms in oral vaccination
- Oral delivery systems (e.g., nanoparticles, liposomes)
- Probiotic or bacterial vectors for vaccine delivery
- Oral vaccines for infectious diseases
- Oral cancer vaccines and tumor antigen delivery
- Overcoming gastrointestinal barriers in vaccine development
- Immunoadjuvants and mucosal targeting strategies
- Comparative studies of oral vs. parenteral immunization

---

### Guest Editor

Dr. Amin Safa

1. Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS National Cancer Institute, 33081 Aviano, Italy
2. Doctoral School in Pharmacological Sciences, University of Padua, 35122 Padova, Italy

---

### Deadline for manuscript submissions

closed (30 April 2026)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/239740](https://mdpi.com/si/239740)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).